Genprex, Inc. CEO Rodney Varner tells Proactive the Texas-based biotech has been granted Fast Track Designation by the FDA for its Oncoprex immunogene therapy to treat lung cancer. Varner says the FDA validation is important, and gives the company more opportunities to meet with the FDA and facilitate the process of drug approval.
Genprex’s CEO discusses data presented by its collaborators at The University of Texas MD Anderson Cancer Center at the recent AACR Tumor Immunology and Immunotherapy Meeting, highlighting how the positive preclinical data shows that Genprex’s TUSC2 gene could help fight some of the most resistant metastatic lung cancers.
Genprex (NASDAQ:GNPX) CEO Rodney Varner tells Proactive Investors that the active ingredient in the biotech firm’s immunogene therapy Oncoprex has been shown to prevent tumor growth in triple-negative breast cancer patients by independent researchers.
Genprex Inc (NASDAQ:GNPX) Chairman and CEO Rodney Varner tells Proactive Investors the biotech has initiated the first phase of branding for its lead drug candidate and has completed the creation and submission of non-proprietary drug name selections to the USAN Council.
Genprex, Inc. (NASDAQ:GNPX) Chairman and Chief Executive Officer, Rodney Varner, updates Proactive Investors on the latest developments with the Texas-based company’s non-small cell lung cancer drug, including positive study results done in humanized mice.
Genprex, Inc. (NASDAQ:GNPX) Chairman and CEO, Rodney Varner, tells Proactive Investors the biotech has moved one step closer to commercializing its flagship drug candidate by retaining pharmaceutical branding agency, Addison Whitney, for the development of its non-proprietary and brand drug name.
Genprex Inc (NASDAQ: GNPX) CEO Rodney Varner tells Proactive Investors that its collaborators from the University of Texas MD Anderson Cancer Center presented positive preclinical data linked to the company’s Oncoprex immunogene therapy for the treatment of lung cancer at the American Association of Cancer Research meeting.
President and Chief Operating Officer, Julien Pham, MD, MPH, delivers a presentation about the company’s unique, leading-edge gene therapies and participated in a discussion panel on the topic of “Novel Therapies at the Cutting Edge of Cancer Research” at NobleConXV.
Speaking on the sidelines of Biotech Showcase 2019, Julien Pham, President and COO of Genprex, describes how the company is using a technology platform which wraps the TUSC2 gene in a cholesterol nanoparticle to create Oncoprex™ which, in combination with erlotinib, is in Phase II testing against NSCLC.
Genprex Inc (NASDAQ:GNPX) COO Julien Pham tells Proactive Investors the clinical-stage gene therapy company has appointed Jan Stevens as its vice president of clinical operations. According to Pham, Stevens will support clinical development programs for the company’s immunogene therapy Oncoprex, which is being evaluated in…